窑Review 窑
Cancer is the leading cause of morbidity and mortality for human beings. With transformations in the medical model and in overall understandings of health with regard to the biopsychosocial model, the management of cancer shifts the focus from the local tumor mass to the status of the whole body, the patient's response to treatment, and qualityoflife. Numerous treatment strategies (surgery, radiotherapy, traditional Chinese medicine, biological therapy, and endocrine treatment) have provided many choices for tumor management, and how to adopt the best treatment strategy to achieve optimal outcomes is the hot spot of much clinical research. Therefore, the evaluation of treatment efficacy is very important. In this review, we outline the current status of clinical assessments for patients with cancer.
The World Health Organization (WHO) introduced their clinical assessment criteria in 1979. The criteria divided outcomes into five categories of complete response (CR), partial response (PR), stable disease (SD) or no change (NC), and progressive disease (PD). It evaluated the clinical effect by comparing the tumor size (multiplying the two diameters of the tumor mass) before and after treatment, and determining that the shortterm effect should be maintained for at least 4 weeks 1 . Nonsolid tumors are divided into CR, PR, and NR according to the proportions of the reduction of tumor cells in the bone marrow. Because this method is simple, objective, and easy to perform, it has been widely used for the assessment of new drugs and treatment strategies.
However, this method doesn't have standards for some aspects. For instance, this method does not specify the size of the smallest mass and the number of lesions that should be evaluated, the criteria of PD is not detailed (whether the evaluation of one lesion is enough or if all lesions should be evaluated), and the widely used evaluation modalities such as computed tomography (CT) and magnetic resonance imaging (MRI) are not mentioned. Thus, evaluations of clinical effect among different studies are heterogeneous and incomparable, which consequently may lead to deviating or wrong conclusions 24 . Additionally, these criteria are also used for the evaluation of the efficacy of TCM, though it is limited. Chen . 5 found that the characteristics of the treatment of cancer with TCM was tumorcarrying survival. The tumor mass does not usually shrink, but the qualityoflife is improved and the survival time is prolonged, in contrast to chemotherapy, which features its tumor cell killing effects. Thus, the WHO criteria cannot evaluate the efficacy of tumor treatment by TCM.
Due to the limitations of the WHO shortterm efficacy evaluation criteria, the European Organization for Research and Treatment of Cancer (EORTC), the US National Cancer Institute (NCI), and the National Cancer Institute of Canada (NCIC) held a seminar to establish novel cr iteria for the treatment effect of solid tumors (RECIST 1.0) 6 . The criteria abrogated the concept of the assessable lesion. Instead, it categorized lesions as measurable or immeasurable and introduced the concept of the target lesion. PD is well defined. The doublediameter measurement was replaced by a singlediameter measurement (the longest one). Thus, it is more accurate and easy to perform than the WHO criteria 7 . However, the definition of PD in RECIST 1.0 requires further investigation and some novel treatment strategies are not elucidated in the criteria. Gong 8 evaluated the therapeutic efficacies of gastrointestinal tumors with this method and found that PD as defined by RECIST 1.0 was not concordant with the actual situation. He proposed that the time of tumor progression (TTP) might be a good index for the assessment of clinical effect.
With the everimproving strategies and drugs for treating cancer, especially with the emerging varieties of noncytotoxic molecular targeting drugs, the American Society of Clinical Oncology (ASCO) and the Radiological Society of North America (RSNA) discussed and revised RECIST 1.0 in 2009. The revised RECIST 1.1 updated the contents with respect to the number of target lesions, the importance of determining effects, and the measurements of lymph nodes. It also specified how to use the new evaluating modalities such as fluorodeoxyglucose positron emission tomography (FDGPET) and MRI 9, 10 . In the assessments of solid tumor response to cytotoxic drugs, the WHO criteria and RECIST both evaluated the effects by measuring tumor size. Actually, their goal is tumorfree survival. Nonetheless, for the cerebral tumors or noncytotoxic drugs, the clinical experience demonstrated that complete remission of the lesion did not necessarily predict an optimal outcome 11 . Thus, the assessment of tumor response should take the following indices into consideration.
For solid tumors, size is commonly used for the assessment of shortterm effects. However, clinical trials demonstrate that reductions in tumor size cannot prolong survival time. In addition, the inclusion of median survival time into the assessment indices is supplementary to the assessment of middle to longterm effects, as well as to the determination of prognosis.
Survival time refers to the period from the treatment to either death or the time of the last followup. It is usually expressed as median survival time. Median survival time is also called halflife, indicating that only 50% of the subjects can survive this period. In addition, it can reflect the prognosis of the tumor: the longer the median survival time, the better the prognosis; the shorter the median survival time, the poorer the prognosis. Commonly used indices include overall survival (OS), median survival time, progressionfree survival (PFS), relapsefree survival (RFS), and distant metastasisfree survival (DMFS). These indices are usually used in research of noncytotoxic drugs. Of them, the OS and PFS are used to reflect the survival benefit to the patient. Similar kinds of indices also include:
Time of tumor progression (TTP), which refers to the time from remission to disease prog ression. It reflects the stability of the disease after treatment. Median TTP is commonly adopted. TTP is suitable for the assessment of cellstabilizing drugs and herbal medicine, which is similar to PFS 8, 12 . Diseasefree survival (DFS), which refers to the period between surgical resection of the tumor and tumor recurrence.
Survival rate (SR), which includes one and fiveyear survival rates, reflects the survival status of patients with cancer in a certain period of observation.
Currently, TCM is a supplementary treatment for alleviating adverse reactions resulting from chemotherapy and radiotherapy and improving survival rates. The survival rate is an index for assessing the effect of TCM. However, the design and research process of most clinical studies are unsophisticated. Thus, the assessment with this method requires more welldesigned, properly conducted studies to verify its effect.
For patients with advanced cancer, reducing or eradicating the local tumor mass is impossible. What's more important is how to alleviate the adverse reactions induced by chemotherapy and radiotherapy, thereby improving qualityoflife (QOL). As proposed by Schipper, 耶effective treatment doesn't mean the complete remission of the tumor, but the response of the body to the treatment strategies爷 13 . In 1985, the US Food and Drug Administration (FDA) also pointed out that the assessment should include both survival time and improvements in QOL 14 .
Patientreported outcomes (PROs) comprised both subjective and objective healthrelated QOL, including patient reported functional status, psychological conditions, symptoms, and healthrelated QOL. Thus, the application of a PRO scale into clinical trials for medical products is meaningful to clinical assessments 15 . The assessment criteria based on QOL are more accurate and mature in theory. QOL refers the subjective evaluations of an individual to his or her own physiologic and psychological status, social ability, and comprehensive conditions in the context of different cultures and value systems. Lane . 16 recommended that QOL should be used to guide the clinician to make decisions.
In actuality, the evaluation of QOL can be difficult, because the content of QOL is inconsistent across studies. Demographic characteristics (cultural background, education level, religion, personality, social status, career, and age) of the subjects may be different, and complications of the cancer and comorbidities may also be different. These may confound the results of the study.
The ideology of TCM in treating cancer is to regain the homeostasis of the human body. Its assessments contain QOL components, including somatic functions, subjective feelings, and selfreported symptoms. Thus, QOL is stressed in the clinical assessment of cancer in TCM and has become important in the field of TCM 17, 18 .
This index was first proposed with the application of gemcitabine hydrochloride (such as gemzer). Gemzer was first used for the treatment of pancreatic cancer but without optimal outcomes, but its effects included controlling symptoms and improving QOL 19 . Items of clinicalbenefit response include the degree of the pain, the dose of analgesics, scores of behavioral status, and changes in body weight. Effectiveness is defined when one of these items improves, whereas the other items are not changed.
The NCI and the FDA have acknowledged that symptom improvement is a valuable goal in the management of cancer 20 . The assessment of treatment effect has transformed from simple observations of shortterm effects to extended survival times and improvements in QOL. Diseaserelated symptom improvement refers to (1) pain alleviation and/or the deescalation of analgesics (from morphine to codeine) and/or Karnofsky Performance Status (KPS) improvement (> 20 points), or (2) the stabilization of these three indices plus an increase in body weight by 7% . Diseaserelated symptom improvement requires an analysis of data collected in daily routines. The goals of diseaserelated symptom improvement and clinicalbenefit response are the same.
QOL might be directly compromised by the cost of treatment. Some investigators contend that overstressing tumorfree survival may lead to overtreatment of the tumor in clinical settings or even iatrogenic injury to the patient. In this circumstance, even though the tumor is cured, the patient is debilitated that cannot live a normal life. The result is the low costeffectiveness and waste of medical resources 21, 22 . Indices concerning costeffectiveness will provide economic evidence for the appropriate use of medical resources and clinical decisionmaking. However, such investigations are rare at present.
Relapse time refers to the time from remission to relapse and is usually expressed by the median time. Effective time is the duration from the initiation of treatment to the reduction in the size of the tumor. Remission period and response rate (RR) are the duration from remission to recurrence (RR = CR + PR + SD). Stable period is the duration from the initiation of treatment to disease progression.
However, these indices (PFS, remission period, and stable period) are influenced by the frequency of followup after the baseline evaluation, the types and stages of the diseases, treatment cycles, and clinical settings. These may compromise the accuracy of the final results.
All pathologic and biochemical indices and imaging studies are essential for the assessment of cancer. With emerging biologic therapies, including targeted therapy and immunotherapy, the functional imaging of PET/CT has been used to assess the effects of cancer treatment. Such indices, as adjunct and intermediate indices, are clinically important to assess the effect on the cancer.
RECIST has incorporated the importance of the various modalities for evaluation (physical examination, chest Xray, CT, MRI, ultrasound, endoscopy, laparoscopy, tumor markers, and cellular and histologic assays) and pointed out that imaging is superior to clinical assessment. . With respect to tumor markers, RECIST pointed out "the tumor marker alone cannot be used to assess the therapeutic effect. However, tumor marker levels that exceed the normal upper limit will return to normal when the tumor lesion is removed and the disease achieves complete remission, indicating that the tumor marker is correlated with the progression of the lesion. Thus, tumor markers can be used as an adjunctive index for the effect assessment 15 .
The treatment of cancer in TCM focuses on the whole body, and its basic principles are different from modern medicine. Thus, scholars of TCM have made every effort to establish the oncologic evaluation system of response to treatment with Chinese characteristics. The TCMOES edited by Zhou . 25 is the most widely used. This system is categorized into two parts: (1) evaluation criteria of tumors in stages III (early, middle stages): total effect assessment criteria (100%) = changes of the tumor mass (40% ) + clinical manifestations (15% ) + physical activity (15% ) + survival time (30% ); (2) evaluation criteria of tumors in stages IIIIV (advanced stages): total effect assessment criteria (100% ) = changes of the tumor mass (30% ) + clinical manifestations (15%) + physical activity (15%) + survival time (40%).
Xue . 26 explored the applicability of this system and found that it can optimally reflect the clinical effect of TCM in the treatment of nonsmall cell lung carcinomas, which was more objective and complete than RECIST. However, this was a retrospective study, lacking strict controls on factors including the general conditions of the patients, treatment strategies, therapeutic courses, clinical manifestations, and the completeness and reliability of the medical records. Thus, more investigations are needed to verify the evaluation system.
The TCM zhenghou evaluation has long been the primary index for the clinical assessment of new TCM drugs. The system progressed from simple symptom evaluation to combined evaluations of symptoms and diseases, the combination of primary and secondary symptoms, as well as the semiquantitative system to assess effect (symptom scoring). The TCM symptom evaluation index is the index that has been progressively completed and improved in new drug clinical trials 27, 28 . TCM zhenghou is based on the whole body that outlines the overall reaction of the body to inner and outer pathogenic factors. This evaluation system is the organic combination of specific symptoms and signs. The disappearance or improvement of signs and symptoms is the manifestations of TCM efficacy. On the other hand, it stresses objective complaints, feelings, and patient participation. Moreover, symptoms are a component of the zhenghou, and the use of this system is to evaluate the changes of the zheng, as well as the differences in effect.
More and more investigators are beginning to emphasize the importance of this index in the clinical assessment of cancer by quantifying and standardizing the system. Yang . 29 pointed out that these indices can reflect the chief complaints of the patients, including pain, dysphagia due to esophageal cancer, gastric hemorrhage of gastric cancer, jaundice or ascites of liver cancer, and cough and hemoptysis of lung cancer. Recovery is defined as the remission of primary signs and symptoms for more than 4 weeks. Stability is defined as consistent primary signs and symptoms, or if the patient has no signs and symptoms related to the tumor. Deterioration is the exacerbation of primary signs and symptoms.
As assessments of effect in cancer treatment mature, TCM and modern medicine both propose comprehensive and integrated evaluations, weighing each index in the evaluation of cancer at different stages and levels. For instance, Shi . 30 contended that QOL, survival time, and tumor remission rates were the primary indices, and specified the importance of these indices in tumor progression, as well as the complexity of the weight coefficient. Wang . 31 used the WHO criteria to evaluate tumor size, KPS for QOL evaluation, and primary symptoms as the assessing indices, and apportioned and weighted scores to each index. Que . 32 recommended that assessments of effect should include three aspects of the adjusted life year (QOL × survival time), zhenghou remission rate, and tumor remission rate. Furthermore, they proposed the weight of these indices in the assessment of effect was related to the different stages and treatment strategies for the cancer. Li . 33 proposed that QOL, TTP, and costeffectiveness should be included in evaluating of TCM treatment efficacy of patients with lung cancer. As a result, the formula should be: optimal QOL + TTP + highest tumor remission rate + appropriate cost/effect.
In addition to assessment with conventional methods, financial burden and clinical benefit should be taken into consideration 33 . The evaluation should include various aspects, including the patient, clinical staff, caretakers, and medical technicians 15, 21 , aiming to evaluate the therapeutic effect comprehensively and to provide evidence for clinical decisionmaking.
In conclusion, it appears that the clinical assessment is progressing from evaluating simple and shortterm effects to the comprehensive evaluation of these effects, and the choice of indices from simple, local, or tumorfree survival principles to systemic, comprehensive, and tumorcarrying survival principles. Although the assessments of TCM and modern medicine are somewhat different, both adopt comprehensive evaluations.
Some investigators contend that the combination of TCM and modern medicine and the internationalization of TCM require new systems to assess therapeutic effect. Despite the disparities between TCM and modern medicine in the assessment of tumor treatment effects, they are not contradictory, and new consensus is expected to be reached 12 .
Currently, there are many problems in assessing treatment effects, including the variability of evaluation indices, the disparity of the contents of the evaluation tools for QOL, the weight of evaluating indices at different stages, and the objectivity in evaluating the effect TCM. With deeper understanding of the indices used for evaluation, the screening, application, and efficiency of assessment by TCM and modern medicine will become more objective, comprehensive, and strictly conducted.
